Rinvoq (upadacitinib) / AbbVie  >>  Phase 2
Welcome,         Profile    Billing    Logout  

21 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rinvoq (upadacitinib) / AbbVie
SELECTSUNRISE, NCT02720523: A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

Checkmark SELECT-SUNRISE trial data in Japanese patients
Apr 2018 - Apr 2018: SELECT-SUNRISE trial data in Japanese patients
Completed
2b
197
Japan
Placebo, Upadacitinib, ABT-494, RINVOQ™
AbbVie
Rheumatoid Arthritis
08/17
06/22
NCT02925117 / 2016-002451-21: A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

Checkmark In atopic dermatitis
Sep 2017 - Sep 2017: In atopic dermatitis
Completed
2b
167
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ™, ABT-494, Placebo
AbbVie
Atopic Dermatitis
08/17
01/19
NCT01960855 / 2013-002358-57: A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy

Checkmark From BALANCE-1 trial for RA
Nov 2016 - Nov 2016: From BALANCE-1 trial for RA
Checkmark For the treatment of rheumatoid arthritis
Sep 2015 - Sep 2015: For the treatment of rheumatoid arthritis
Completed
2
276
NA
ABT-494, Placebo
AbbVie
Rheumatoid Arthritis
07/15
07/15
NCT02066389 / 2013-003984-72: A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Checkmark EULAR 2016
Jun 2016 - Jun 2016: EULAR 2016
Checkmark For the treatment of rheumatoid arthritis
Sep 2015 - Sep 2015: For the treatment of rheumatoid arthritis
Completed
2
300
Europe, US, RoW
Placebo, Upadacitinib, ABT-494
AbbVie
Rheumatoid Arthritis
07/15
07/15
CELEST, NCT02365649 / 2014-003240-12: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Checkmark At DDW 2017
May 2017 - May 2017: At DDW 2017
Completed
2
220
NA
Placebo, ABT-494, Upadacitinib
AbbVie
Crohn's Disease
11/16
08/17
SELECT Axis 1, NCT03178487 / 2017-000431-14: A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Checkmark Data from SELECT Axis 1 trial for ankylosing spondylitis at ACR 2020
Nov 2020 - Nov 2020: Data from SELECT Axis 1 trial for ankylosing spondylitis at ACR 2020
Completed
2
187
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ™, Placebo
AbbVie
Ankylosing Spondylitis (AS)
01/19
02/22
NCT03682705 / 2018-000666-10: A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Completed
2
242
Europe, Canada, US, RoW
Elsubrutinib, ABBV-105, Upadacitinib, ABT-494, Placebo for elsubrutinib, Placebo for upadacitinib
AbbVie
Rheumatoid Arthritis (RA)
03/20
03/20
NCT03823378 / 2018-002306-31: A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Terminated
2
97
Europe, Canada, RoW
Elsubrutinib, ABBV-105, Upadacitinib, ABT-494, Placebo for elsubrutinib, Placebo for upadacitinib
AbbVie
Rheumatoid Arthritis (RA)
09/20
09/20
NCT04430855: A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Completed
2
68
Canada, Japan, US
Upadacitinib, RINVOQ, Placebo
AbbVie
Hidradenitis Suppurativa (HS)
04/21
01/22
BALANCE-EXTEND, NCT02049138 / 2013-003530-33: An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Completed
2
493
Europe, US, RoW
Upadacitinib, ABT-494, RINVOQ®, Pneumococcal 13-valent conjugate vaccine (PCV-13), Prevnar 13®
AbbVie
Rheumatoid Arthritis
07/21
07/21
2021-000081-15: A clinical study to evaluate the safety and benefit of upadacitinib in patients with Vitiligo.

Not yet recruiting
2
160
Europe
Upadacitinib, ABT-494, Film-coated tablet
AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
Vitiligo, Vitiligo, Diseases [C] - Immune System Diseases [C20]
 
 
SLEek, NCT03978520 / 2019-000638-20: A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Completed
2
341
Europe, Canada, Japan, US, RoW
Elsubrutinib, ABBV-105, Placebo for elsubrutinib, Upadacitinib, RINVOQ, Placebo for upadacitinib
AbbVie
Systemic Lupus Erythematosus (SLE)
01/22
07/22
NCT04927975 / 2021-000081-15: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Jan 2023 - Dec 2023: Early or mid stage data readout from trial for vitiligo
Completed
2
185
Europe, Canada, Japan, US
Upadacitinib, ABT-494, RINVOQ, Placebo
AbbVie, AbbVie Inc.
Non-Segmental Vitiligo
01/23
08/23
NCT04451772 / 2020-001690-72: A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

Completed
2
185
Europe, Japan, US, RoW
Elsubrutinib, ABBV-105, Placebo for Elsubrutinib, Upadacitinib, ABT-494, RINVOQ, Placebo for Upadacitinib
AbbVie
Systemic Lupus Erythematosus (SLE)
01/24
01/24
NCT07080346: Upadacitinib for Refractory Behcet's Syndrome

Completed
2
27
RoW
Upadacitinib 15 MG
Liu Tian
Behcet Syndrome
12/24
07/25
2021-006031-25: Investigation of a new treatment strategy for patients with the severe skin disease Lichen planus Untersuchung einer neuen Behandlungsstrategie für Patienten mit der schweren Hauterkrankung Lichen planus

Completed
2
22
Europe
Upadacitinib, Prolonged-release tablet
Charité - Universitätsmedizin Berlin, Abbvie
Patients with the chronic inflammatory skin disease Lichen planus will be treated with the JAK inhibitor upadacitinib. Patienten, die an der chronisch inflammatorischen Hauterkrankung Lichen planus leiden, werden mit dem JAK Inhibitor Upadacitinib behandelt., Patients with a skin disease (Lichen planus) will be treated with a substance that reduces the action of the immune system Patienten mit einer Hauterkrankung (Lichen planus) werden mit einer Substanz behandelt, die die Aktivität des Immunsystems reduziert., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT06862284: Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Not yet recruiting
2
30
RoW
Upadacitinib (ABT-494), Hydroxychloroquine (HCQ)
Peking University People's Hospital
Primary Sjögren's Syndrome (pSS)
12/26
08/27
NCT07064889: The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Not yet recruiting
2
132
RoW
Dexamethasone, Upadacitinib
Peking University People's Hospital, Beijing Hospital, Navy General Hospital, Beijing, Beijing Aerospace General Hospital, Qilu Hospital of Shandong University, Beijing Tongren Hospital
Immune Thrombocytopenia
07/27
12/27
NCT07138898: Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not yet recruiting
2
80
US
Methotrexate, Sulfasalazine, Hydroxychloroquine, Plaquenil, Leflunomide, Arava, Azathioprine, Imuran, Mycophenolate, Cellcept, Cyclosporine, Tacrolimus, Etanercept, Enbrel, Adalimumab, Humira, Golimumab, Simponi, Certolizumab, Cimzia, Infliximab, Remicaide, Rituximab, Rituxan, Belimumab, Benlysta, Tocilizumab, Actemra, Anakinra, Kineret, Canakinumab, Ilaris, Abatacept, Orencia, Secukinumab, Cosentyx, Ixekizumab, Taltz, Bimekizumab, Bimzelx, Ustekinumab, Stelara, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tofacitinib, Xeljanz, Upadacitinib, Rinvoq
NYU Langone Health
Rheumatic Disease
09/27
09/27
NCT02782663 / 2015-003759-23: A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

Completed
2
107
Europe, Canada, US, RoW
ABT-494, Upadacitinib, RINVOQ
AbbVie
Crohn's Disease (CD)
07/25
07/25
NCT06873100: Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Recruiting
1/2
30
RoW
Upadacitinib, corticosteroids and immunosuppressants
Peking University People's Hospital
Relapsing Polychondritis
08/26
12/26

Download Options